科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

未开盘 04-03 16:08:16

14.680

-0.480

-3.17%

最高15.360	最低14.300	成交量283.25万
今开15.140	昨收15.160	日振幅6.99%
总市值84.12亿	流通市值84.12亿	总股本5.73亿
成交额4,165万	换手率0.49%	流通股本5.73亿
市净率7.47	ROE-55.84%	每股收益-1.54
52周最高19.780	52周最低2.480	市盈率-9.55
股息0.00	股息收益率0.00	ROA-17.90%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":14.68,"timestamp":1743667696030,"preClose":15.16,"halted":0,"volume":2832500,"delay":0,"floatShares":573000000,"shares":573000000,"eps":-1.5377589811836945,"marketStatus":"未开盘","change":-0.48,"latestTime":"04-03 16:08:16","open":15.14,"high":15.36,"low":14.3,"amount":41650400,"amplitude":0.069921,"askPrice":14.68,"askSize":3500,"bidPrice":14.58,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-1.5377589811836945,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1743989400000},"marketStatusCode":0,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":15.16,"openAndCloseTimeList":[[1743643800000,1743652800000],[1743656400000,1743667200000]],"volumeRatio":0.680678085645837,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2518475090","title":"科济药业-B盘中异动 下午盘快速跳水5.03%报13.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518475090","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518475090?lang=zh_cn&edition=full","pubTime":"2025-03-11 13:19","pubTimestamp":1741670393,"startTime":"0","endTime":"0","summary":"2025年03月11日下午盘13时19分，科济药业-B股票出现异动，股价大幅下挫5.03%。截至发稿，该股报13.980港元/股，成交量263.715万股，换手率0.46%，振幅4.08%。资金方面，该股资金流入1240.98万港元，流出2192.2万港元。科济药业-B股票所在的生物技术行业中，整体涨幅为0.71%。其相关个股中，帝王国际投资、荃信生物-B、华领医药-B涨幅较大，振幅较大的相关个股有帝王国际投资、华领医药-B、方达控股，振幅分别为100.00%、17.04%、15.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311131953abf58a42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311131953abf58a42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1574","02171","BK1161","BK1587"],"gpt_icon":0},{"id":"2518138212","title":"科济药业-B03月10日遭主力抛售1281万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518138212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518138212?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:17","pubTimestamp":1741594648,"startTime":"0","endTime":"0","summary":"03月10日, 科济药业-B股价跌8.34%，报收14.72元，成交金额1.33亿元，换手率1.62%，振幅15.07%，量比1.04。科济药业-B今日主力资金净流出1281万元，上一交易日主力净流出489万元。该股近5个交易日下跌6.30%，主力资金累计净流出841万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入9753万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170925abf2987f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170925abf2987f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1587","02171","BK1585"],"gpt_icon":0},{"id":"2518548582","title":"被调出港股通名单，科济药业盘中跌超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518548582","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518548582?lang=zh_cn&edition=full","pubTime":"2025-03-10 10:24","pubTimestamp":1741573466,"startTime":"0","endTime":"0","summary":"3月10日，科济药业股价开盘后大跌。截至发稿前，科济药业盘中跌超13%，股价报13.84港元/股。3月7日，上交所发布《关于沪港通下港股通标的调整的通知》，因恒生综合大型股指数、中型股指数、小型股指数实施成份股调整，沪港通下港股通标的名单发生调整，并自下一港股通交易日（即2025年3月10日）起生效。其中，科济药业、康宁杰瑞制药、来凯医药等多家Biotech均在调出名单内。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503103341031515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4614","HSCEI","YANG","02171","BK1587","BK1574","BK1585","BK1161","HSTECH"],"gpt_icon":0},{"id":"2518254852","title":"港股通证券名单调整 被剔出个股股价普跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2518254852","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518254852?lang=zh_cn&edition=full","pubTime":"2025-03-10 10:12","pubTimestamp":1741572727,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上交所和深交所分别发布公告称，鉴于恒生综合大型股指数、中型股指数、小型股指数实施成份股定期调整，相应对纳入及调出港股通交易范围的证券名单进行调整，此次调整于3月10日生效。调整生效后，被剔出港股通名单的个股股价普遍呈现下跌态势。其中，京基金融国际(01468)表现最为疲软，当前股价下跌32%，报0.255港元。此外，宜明昂科-B(01541)股价下跌11.58%；来凯医药-B(02105)下跌16.69%；科济药业-B(02171)下跌14.32%；科笛(02487)下跌12.99%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954670","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1181","BK1161","BK1585","07226","161027","01541","01468","YANG","02171","BK1138","BK1574","BK1587","HSCEI","HSTECH","BK4614","02105","02487"],"gpt_icon":0},{"id":"2518258529","title":"深交所发布关于深港通下的港股通标的证券名单调整的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2518258529","media":"深交所网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518258529?lang=zh_cn&edition=full","pubTime":"2025-03-10 08:58","pubTimestamp":1741568314,"startTime":"0","endTime":"0","summary":"因恒生综合大型股指数、中型股指数、小型股指数实施成份股定期调整,根据《深圳证券交易所深港通业务实施办法》的有关规定，港股通标的证券名单发生调整并自2025年03月10日起生效，相关调整信息如下：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310085053a269149e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02411","00410","BK1582","01119","02431","02570","00095","02799","BK1240","HSCEI","02522","HSTECH","02410","06639","02582","03939","02407","02510","02562","02507","00308","01541","00743","01468","02460","01942","02506","02577","03650","01268","09985","09959","02121","01600","02105","02432","02487","02587","00041","02586","02232","03669","02678","06623","01799","02150","02461","09966","BK1555","00697","02423","06660","00659","00999","01318","02171","06698","09869","03309"],"gpt_icon":0},{"id":"2517136755","title":"科济药业-B03月06日获主力加仓492万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517136755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517136755?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:16","pubTimestamp":1741248993,"startTime":"0","endTime":"0","summary":"03月06日, 科济药业-B股价涨5.26%，报收16.00元，成交金额1.15亿元，换手率1.27%，振幅7.11%，量比0.52。科济药业-B今日主力资金净流入492万元，上一交易日主力净流入646万元。该股近5个交易日下跌4.53%，主力资金累计净流入2019万元；近20日主力资金累计净流入1.11亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165823abeb1358&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165823abeb1358&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1574","02171","BK1587","BK1161"],"gpt_icon":0},{"id":"2517189469","title":"港股异动 | 科济药业-B(02171)涨近7% Claudin18.2 CAR-T纳入突破性治疗药物品种 有望上半年申请上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2517189469","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517189469?lang=zh_cn&edition=full","pubTime":"2025-03-06 15:14","pubTimestamp":1741245299,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B涨近7%，截至发稿，涨4.74%，报15.92港元，成交额1.01亿港元。消息面上，科济药业近日宣布，公司自主研发的舒瑞基奥仑赛注射液已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。此次增资完成后，公司的权益将由100%稀释至92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4022","BK4230","BK1161","BK1574","BK1587","CAR","02171","BK1585"],"gpt_icon":0},{"id":"2517318854","title":"科济药业-B盘中异动 下午盘急速上涨5.00%报15.960港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517318854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517318854?lang=zh_cn&edition=full","pubTime":"2025-03-06 13:11","pubTimestamp":1741237872,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘13时11分，科济药业-B股票出现异动，股价快速拉升5.00%。截至发稿，该股报15.960港元/股，成交量434.15万股，换手率0.76%，振幅5.00%。科济药业-B股票所在的生物技术行业中，整体涨幅为0.35%。2月26日，科济药业公告披露，旗下优恺泽生物完成珠海软银主导的8000万元战略融资，对应估值达10亿元。科济药业的转型之路颇具行业启示意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306131112963baef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306131112963baef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1585","BK1574","02171","BK1587"],"gpt_icon":0},{"id":"2517188360","title":"华东医药：公司与科济药业合作进行商业化的赛恺泽 产品目前市场拓展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2517188360","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517188360?lang=zh_cn&edition=full","pubTime":"2025-03-06 13:04","pubTimestamp":1741237440,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n　　证券之星消息，华东医药(000963)03月05日在投资者关系平台上答复投资者关心的问题。　　投资者：贵公司今后还有没有和科济药业继续合作的项目？　　华东医药董秘：您好！公司与科济药业合作进行商业化的赛恺泽产品目前市场拓展顺利。今后公司如有进一步的对外合作计划，将按照信息披露相关规定及时公告。感谢您的关注！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-03-06/doc-inenswir0946806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1587","BK0175","LU1969619763.USD","BK1161","BK1585","BK0187","02171","BK0183","BK0188","BK0209","BK0196","LU2328871848.SGD","BK1574","BK0132","000963"],"gpt_icon":0},{"id":"2517960367","title":"CAR-T的“资本寒冰”开始融化","url":"https://stock-news.laohu8.com/highlight/detail?id=2517960367","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517960367?lang=zh_cn&edition=full","pubTime":"2025-03-05 16:22","pubTimestamp":1741162931,"startTime":"0","endTime":"0","summary":"在市场情绪最低落的时候，事情却悄然发生转机，艺妙神州、科济药业纷纷在近期宣布完成CAR-T融资协议，禁锢CAR-T产业的“寒冰”正在开始融化。这一融资金额虽然并不够，但考虑到通用型CAR-T依然处于临床早期阶段，表明资本已经开始将通用型CAR-T纳入估值体系。国内特殊的支付环境是CAR-T发展的最大障碍。科济药业与珠海软银的此次合作，或将成为CAR-T“资本寒冰”溶解的标志性事件。此外，CAR-T治疗实体瘤失败的案例更是频发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305162228963a6e0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305162228963a6e0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1587","02171","BK1585"],"gpt_icon":0},{"id":"2517956905","title":"科济药业-B盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517956905","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517956905?lang=zh_cn&edition=full","pubTime":"2025-03-05 11:11","pubTimestamp":1741144271,"startTime":"0","endTime":"0","summary":"2025年03月05日早盘11时11分，科济药业-B股票出现异动，股价大幅下跌5.08%。截至发稿，该股报14.940港元/股，成交量458.65万股，换手率0.80%，振幅6.61%。科济药业-B股票所在的生物技术行业中，整体涨幅为0.97%。科济药业-B公司简介：科济药业控股有限公司是一家主要从事创新嵌合抗原受体T 细胞疗法发现、开发及销售业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305111112abe8ce8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305111112abe8ce8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1587","BK1574","BK1585","BK1161"],"gpt_icon":0},{"id":"2516872522","title":"港股异动 | 科济药业-B(02171)涨超6% Claudin18.2 CAR-T舒瑞基奥仑赛注射液纳入突破性治疗药物品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2516872522","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516872522?lang=zh_cn&edition=full","pubTime":"2025-03-03 09:48","pubTimestamp":1740966496,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B涨超6%，截至发稿，涨6.14%，报16.94港元，成交额5500.42万港元。消息面上，科济药业今早宣布，公司自主研发的舒瑞基奥仑赛注射液已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1161","BK4022","CAR","02171","BK4230","BK1574","BK1585"],"gpt_icon":0},{"id":"2516156524","title":"科济药业-B(02171)上涨5.26%，报16.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516156524","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516156524?lang=zh_cn&edition=full","pubTime":"2025-03-03 09:40","pubTimestamp":1740966056,"startTime":"0","endTime":"0","summary":"3月3日，科济药业-B盘中上涨5.26%，截至09:40，报16.8元/股，成交4458.21万元。科济药业控股有限公司是一家专注于开发创新嵌合抗原受体T细胞疗法，治疗实体瘤和血液恶性肿瘤的生物制药公司。截至2024年中报，科济药业-B营业总收入634.0万元、净利润-3.52亿元。3月18日，科济药业-B将披露2024财年年报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/03094048477493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1574","BK1587","02171","BK1585"],"gpt_icon":0},{"id":"2516524210","title":"科济药业-B盘中异动 早盘股价大涨5.01%报16.760港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516524210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516524210?lang=zh_cn&edition=full","pubTime":"2025-03-03 09:30","pubTimestamp":1740965433,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时30分，科济药业-B股票出现波动，股价大幅上涨5.01%。截至发稿，该股报16.760港元/股，成交量143.35万股，换手率0.25%，振幅1.88%。资金方面，该股资金流入55.816万港元，流出216.311万港元。科济药业-B股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，永泰生物-B、科济药业-B、再鼎医药涨幅较大，振幅较大的相关个股有永泰生物-B、乐普生物-B、来凯医药-B，振幅分别为6.79%、4.11%、2.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030309303398992613&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030309303398992613&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1585","02171","BK1587","BK1161"],"gpt_icon":0},{"id":"2516357538","title":"科济药业Claudin18.2 CAR-T舒瑞基奥仑赛注射液纳入突破性治疗药物品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2516357538","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516357538?lang=zh_cn&edition=full","pubTime":"2025-03-03 08:15","pubTimestamp":1740960900,"startTime":"0","endTime":"0","summary":"公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。\" 关于舒瑞基奥仑赛注射液 舒瑞基奥仑赛注射液是一种潜在全球同类首创的、靶向Claudin18.2蛋白的自体CAR-T细胞候选产品，用于治疗Claudin18.2阳性实体瘤，主要治疗胃癌/食管胃结合部腺癌及胰腺癌。2020年9月，舒瑞基奥仑赛注射液被美国FDA授予\"孤儿药\"认定用于治疗胃癌/食管胃结合部腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4630020_ZH30020_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","CAR","BK1587","BK4230","02171","BK4022","BK1585"],"gpt_icon":0},{"id":"2516939315","title":"多家港股创新药企开年股价翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2516939315","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516939315?lang=zh_cn&edition=full","pubTime":"2025-03-02 10:18","pubTimestamp":1740881939,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","YANG","BK1583","159992","06978","HSTECH","BK1161","159718","02142","HSCEI","07226","BK1587","02171","BK1585"],"gpt_icon":0},{"id":"2514244392","title":"全球首款实体瘤CAR-T细胞产品突破性疗法获批在即，科济药业（02171）率先破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2514244392","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514244392?lang=zh_cn&edition=full","pubTime":"2025-02-28 14:21","pubTimestamp":1740723706,"startTime":"0","endTime":"0","summary":"2月28日，根据中国国家药品监督管理局官网显示，本日为全球首款实体瘤CAR-T细胞产品科济药业舒瑞基奥仑赛注射液突破性治疗药物认定程序公示期最后一日，获批在即。若最终获批，不仅在于其针对特定肿瘤标志物的精准打击能力，更在于它代表了CAR-T疗法在实体瘤治疗领域的一次重大飞跃。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK4230","BK1574","BK4022","CAR","02171","BK1587","BK1161"],"gpt_icon":0},{"id":"2514033369","title":"科济药业-B盘中异动 股价大跌5.01%报15.920港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514033369","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514033369?lang=zh_cn&edition=full","pubTime":"2025-02-28 09:55","pubTimestamp":1740707738,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时55分，科济药业-B股票出现波动，股价大幅跳水5.01%。截至发稿，该股报15.920港元/股，成交量190.3万股，换手率0.33%，振幅8.11%。资金方面，该股资金流入967.676万港元，流出1723.14万港元。科济药业-B股票所在的生物技术行业中，整体涨幅为1.45%。其相关个股中，百济神州、正大企业国际、方达控股涨幅较大，振幅较大的相关个股有科笛-B、腾盛博药-B、宜明昂科-B，振幅分别为14.48%、12.44%、12.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228095538a2571c2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228095538a2571c2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1574","BK1161","02171","BK1585"],"gpt_icon":0},{"id":"2514036968","title":"科济药业通用型CD19/CD20 CAR-T产品完成首例自身免疫性疾病受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2514036968","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514036968?lang=zh_cn&edition=full","pubTime":"2025-02-28 08:15","pubTimestamp":1740701700,"startTime":"0","endTime":"0","summary":"上海2025年2月28日 /美通社/ --科济药业，一家主要专注于治疗血液恶性肿瘤和实体瘤的创新CAR-T细胞疗法公司宣布，公司自主研发的一款靶向CD19/CD20的通用型CAR-T细胞治疗候选产品KJ-C2219，已在研究者发起的临床试验中完成首例以临床方案中起始剂量输注的系统性红斑狼疮受试者给药。在此平台下的通用型BCMA或CD19/CD20双靶CAR-T在NK存在时都显示出极强的抗肿瘤疗效，表明该平台可广泛用于多种通用型CAR-T细胞的研制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4628983_ZH28983_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["02171","BK1161","BK4022","BK1587","CAR","BK1585","BK4230","BK1574"],"gpt_icon":0},{"id":"2514503623","title":"科济药业引资8000万，加速CAR-T产品国内进程！","url":"https://stock-news.laohu8.com/highlight/detail?id=2514503623","media":"生物药大时代","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514503623?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:32","pubTimestamp":1740699123,"startTime":"0","endTime":"0","summary":"2月26日，科济药业发布公告，公司及若干附属公司与珠海横琴软银欣创股权投资管理企业旗下管理的基金达成协议。本次增资完成后，科济药业于优恺泽的权益将由100% 稀释至92%。优恺泽是一家在中国内地专注于利用通用型CAR-T细胞疗法治疗血液瘤的新药研发公司。根据协议，优恺泽获得科济药业治疗多发性骨髓瘤、浆细胞白血病的通用型BCMA CAR-T细胞产品以及治疗B细胞肿瘤的通用型CD19/CD20 CAR-T 细胞产品在中国内地的研发、生产与商业化的独家权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228080614a256fab1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228080614a256fab1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1587","02171","BK1585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":0.028},{"period":"1month","weight":-0.0673},{"period":"3month","weight":0.5244},{"period":"6month","weight":2.1036},{"period":"1year","weight":1.3601},{"period":"ytd","weight":0.5939}],"compareEarnings":[{"period":"1week","weight":-0.0309},{"period":"1month","weight":-0.004},{"period":"3month","weight":0.1564},{"period":"6month","weight":0.005},{"period":"1year","weight":0.3662},{"period":"ytd","weight":0.1391}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事创新嵌合抗原受体（CAR）T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。该公司已开发升级版靶向B细胞成熟抗原（BCMA）的CAR-T产品CT053。CT053为其的唯一核心候选产品。该公司在中国和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.109168},{"month":2,"riseRate":0.75,"avgChangeRate":0.310052},{"month":3,"riseRate":0,"avgChangeRate":-0.128154},{"month":4,"riseRate":0,"avgChangeRate":-0.106338},{"month":5,"riseRate":0.666667,"avgChangeRate":0.010432},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.000476},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003478},{"month":8,"riseRate":0.5,"avgChangeRate":0.066002},{"month":9,"riseRate":0.5,"avgChangeRate":0.083194},{"month":10,"riseRate":0.75,"avgChangeRate":0.067361},{"month":11,"riseRate":0.5,"avgChangeRate":0.049974},{"month":12,"riseRate":0.5,"avgChangeRate":-0.036587}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}